Page results
-
The National Hospital for Neurology and Neurosurgery (NHNN) has one of the largest, most comprehensive programmes in Europe for the evaluation and medical and surgical treatment of epilepsy.
-
The Headache Service provides advice and treatment to patients referred for the management of all headache disorders.
-
Our team deliver care to people with MS and aim to provide specialist services, share information on how to manage symptoms, offer education sessions, medication options and rehabilitation services.
-
The Neurometabolic unit provides a unique range of investigations and clinical laboratory advice encompassing mitochondrial, neurotransmitter, pterin and amino acid disorders.
-
The clinical management of neuromuscular muscle wasting diseases such as motor neuron disease, myasthenia gravis, muscular dystrophy and peripheral neuropathy.
-
Typically, patient care is multidisciplinary led by consultant neuro-ophthalmologists and neurologists.
-
The department is responsible for a wide range of neurophysiological procedures, principally electromyography (EMG) and nerve conduction studies, EMG-guided botulinum toxin (BoTox) injections, electroencephalography (EEG), evoked potentials (EPs) and intra-operative monitoring (IOM)
-
The plasma exchange service at the National Hospital treats patients with neuroimmunological diseases such as Guillain-Barré syndrome and myasthenia gravis.
-
This patient information offers advice for patients suffering from long COVID regarding a healthy diet and nutrition.
-
We provide a specialist spinal surgery service including treatment of degenerative spinal conditions, artificial discs, spinal injury, spinal tumours (intra and extra dural, including metastatic disease), scoliosis and syringomyelia.
File results
-
FOI/2023/0330 - Outsourced/ in-house occupational health provisions
-
FOI/2023/0313 - Consent, confidentiality and information sharing in mental healthcare and suicide
-
FOI/2023/0315 - Menopause Lead at the Trust
-
FOI/2023/0319 - Multiple Sclerosis (MS) treatment/ medication for any diseases
-
FOI/2023/0323 - Medications/ treatment for dermatology and respiratory medicine
-
FOI/2023/0326 - Risk management system reporting rates for adverse events
-
FOI/2023/0327 - NHS long-term plan/ prevention strategy
-
FOI/2023/0342 - Self-administration of medication policies
-
FOI/2023/0344 - Number of neonatal and stillbirth deaths since January 2013
-
FOI/2023/0343 - Clinical guidelines - group B Streptococcus for antenatal, intrapartum and postnatal care